Ensign Peak Advisors, Inc Adaptive Biotechnologies Corp Transaction History

Ensign Peak Advisors, Inc

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 12, 2022	SELL	$6.4 - $14.73 $93,196 - $214,498	-14,562 Reduced 49.76%	14,700 $119,000
Q1 2022 May 16, 2022	SELL	$10.12 - $28.9 $443,579 - $1.27 Million	-43,832 Reduced 59.97%	29,262 $406,000
Q4 2021 Feb 11, 2022	SELL	$25.17 - $36.85 $250,944 - $367,394	-9,970 Reduced 12.0%	73,094 $2.05 Million
Q3 2021 Nov 12, 2021	BUY	$30.02 - $39.87 $181,080 - $240,495	6,032 Added 7.83%	83,064 $2.82 Million
Q2 2021 Aug 13, 2021	SELL	$32.22 - $44.59 $184,008 - $254,653	-5,711 Reduced 6.9%	77,032 $3.15 Million
Q1 2021 May 12, 2021	SELL	$37.26 - $67.74 $461,465 - $838,959	-12,385 Reduced 13.02%	82,743 $3.33 Million
Q4 2020 Feb 12, 2021	SELL	$45.01 - $65.47 $823,818 - $1.2 Million	-18,303 Reduced 16.14%	95,128 $5.63 Million
Q3 2020 Nov 12, 2020	BUY	$35.79 - $48.81 $1.88 Million - $2.56 Million	52,549 Added 86.31%	113,431 $5.52 Million
Q2 2020 Aug 12, 2020	SELL	$24.95 - $48.38 $189,595 - $367,639	-7,599 Reduced 11.1%	60,882 $2.95 Million
Q1 2020 May 11, 2020	BUY	$16.96 - $34.16 $1.02 Million - $2.05 Million	60,033 Added 710.62%	68,481 $1.9 Million
Q4 2019 Feb 14, 2020	BUY	$24.56 - $32.8 $207,482 - $277,094	8,448 New	8,448 $252,000

202

146M

68.8K

42.5K

Ticker ADPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 142,872,992
Market Cap $849M
Description
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ, a platform and core immunosequencing product that is used to answer translational research questions, as well as to discover new prognostic and diagnostic signal...

Get notified when there are updates to the investment portfolio of Ensign Peak Advisors, Inc, based on Form 13F filings with the SEC.

Stay updated on Ensign Peak Advisors, Inc with notifications on news.